Home > Insider Trading > Filing (0001140361-14-046759)

Filing Details

Accession Number:: 0001140361-14-046759
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-12-30 19:37:27
Reporting Period:: 2014-12-26

Filing Date:: 2014-12-30
Accepted Time:: 2014-12-30 19:37:27
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1302573	Oncomed Pharmaceuticals Inc	OMED	Pharmaceutical Preparations (2834)	383572512

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1297000	Denise Pollard-Knight	C/O Oncomed Pharmaceuticals, Inc. 800 Chesapeake Drive Redwood City CA 94063		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2014-12-26	2,195	$21.65	1,962,720	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2014-12-29	9,902	$21.62	1,952,818	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2014-12-30	5,510	$21.65	1,947,308	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

This transaction was executed in multiple trades in prices ranging from $21.60 to $21.72, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The shares of common stock of OMED are owned by Phase4 Ventures III LP ("Phase4"). The Reporting Person is a partner of Phase4 Partners Limited, which is the manager of Phase4. The Reporting Person disclaims beneficial ownership of the reported securities held by Phase4 except to the extent of her pecuniary interest therein.
This transaction was executed in multiple trades in prices ranging from $21.60 to $21.65, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
This transaction was executed in multiple trades in prices ranging from $21.60 to $21.78, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.